Up to $1.5 million in grant funding for innovative drugs and devices targeting diabetes and cardiovascular disease

The Medical Research Future Fund (MRFF) Targeted Translation Research Accelerator (TTRA) will offer grant funding up to $1.5 million to support development of innovative preventative, diagnostic, therapeutic and/or disease management drugs and devices for cardiovascular disease and the complication of diabetes (type 1 and type 2).

Eligibility: The lead applicant must

• Be a registered Australian based for-profit business

• Be incorporated in Australia

• Have an Australian Business Number (ABN)

• Have less than 20 employees

• Not be a technology transfer office / mechanism for a university or medical research institute, even with a unique ABN

• Demonstrate capacity to match the cash co-contribution obligation

• Have a drug or medical device that addresses cardiovascular disease or the complications of diabetes

• Drugs must be at least entering formal pre-clinical development stage

• Devices must meet the TGA definition of a medical device and be at least entering TRL4

• Applicant must control or have the legal right to access and use the relevant know-how and/or existing and/or potential Intellectual Property that will be necessary to undertake the project activities and commercialise the product / solution

• Must beet any applicable timing, formatting, system or other administrative requirements during the application process

For more information visit this webpage here, download the program guidelines here or contact the TTRA team via email (accelerator@mtpconnect.org.au).

Expressions of Interest must be submitted by 4pm (AEDT) on 4th November 2024 via the MTPConnect Accelerator grants application portal here.